IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update
May 30, 2023 07:00 ET
|
IGM Biosciences, Inc.
– Event to be webcast live on Friday, June 2, 2023 at 7:00 p.m. ET – MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology...
IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 12, 2023 09:05 ET
|
IGM Biosciences, Inc.
– Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway – – Plans to present additional non-randomized clinical data for 3 mg/kg of...
IGM Biosciences to Present at Two Upcoming Investor Conferences
May 02, 2023 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days
April 19, 2023 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2023
April 13, 2023 16:05 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 30, 2023 16:05 ET
|
IGM Biosciences, Inc.
– Encouraging initial data from IGM-8444 combination with FOLFIRI; first patient dosed in randomized trial – – Imvotamab to move forward into clinical studies in multiple autoimmune diseases – –...
IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023
March 27, 2023 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference
February 02, 2023 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors
January 17, 2023 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
January 09, 2023 07:00 ET
|
IGM Biosciences, Inc.
– Initial Data from Phase 1 combination with FOLFIRI shows promising activity in heavily pretreated metastatic colorectal cancer patients – – Encouraging safety profile in combination with FOLFIRI...